Review
Copyright ©The Author(s) 2024.
World J Radiol. Jun 28, 2024; 16(6): 139-167
Published online Jun 28, 2024. doi: 10.4329/wjr.v16.i6.139
Table 1 Technical considerations for computed tomography and magnetic resonance imaging

CT
MRI
Recommended equipmentMultidetector CT with minimum of 8 detector rows1.5 Tesla or 3 Tesla
≤ 5 mm axial reconstructed slice thicknessPhased array multichannel torso coil
Dual-chamber injector with a saline flushCurrent-generation high-speed gradients
Dual-chamber power injector
Contrast injection rate≥ 3 mL/s of contrast, ≥ 300 mg iodine/mL2-3 mL/s of gadolinium chelate
1.5 mL/kg of body weight
Required imagesArterial phase (late arterial phase strongly preferred over early arterial phase)Unenhanced T1-weighted in phase and opposed phase imaging
Portal venous phaseT2-weighted imaging (fat suppression optional)
Delayed phaseAll contrast agents: Multiphase T1-weighted imaging, preferably using a three dimensional sequence with ≤ 5 mm slice thickness
Pre-contrast imaging
Arterial phase (late arterial phase strongly preferred over early arterial phase)
Portal venous phase
MRI with extracellular contrast agents or gadobenate dimeglumine
Delayed phase (2 to 5 minutes after injection)
MRI with gadoxetate disodium
Transitional phase (2 to 5 minutes after injection)
Hepatobiliary phase (about 20 minutes after injection)
Suggested imagesPre-contrast, for initial diagnosis and patients treated with local-regional therapyMulti-planar acquisition
Multi-planar reformationsSubtraction imaging
Thinner slices with section thickness ≤ 3 mmDiffusion-weighted imaging
1-3 hours hepatobiliary phase with gadobenate dimeglumine
Dynamic phasesBolus tracking or fixed timed delay is suggestedBolus tracking or fixed timed delay is suggested
Table 2 Variants of incidental liver lesions and recommended appropriate imaging recommended by American College of Radiology
Variants
Initial imaging
Size
Extrahepatic malignancy
Underlying chronic liver disease
Appropriate imaging
Variant 1US> 1 cmNoNoUS abdomen with IV contrast
MRI abdomen without and with IV contrast
CT abdomen with IV contrast multiphase
Variant 2CT (non-contrast or single-phase)> 1 cmNoNoMRI abdomen without and with IV contrast
MRI (non-contrast)CT abdomen with IV contrast multiphase
Variant 3US> 1 cmYesNoMRI abdomen without and with IV contrast
CT abdomen with IV contrast multiphase
Variant 4CT (non-contrast or single-phase)> 1 cmYesNoMRI abdomen without and with IV contrast
MRI (non-contrast)CT abdomen with IV contrast multiphase
FDG-PET/CT skull base to mid-thigh
Variant 5US> 1 cmNoYesUS abdomen with IV contrast
CT (non-contrast or single-phase)MRI abdomen without and with IV contrast
MRI (non-contrast)CT abdomen with IV contrast multiphase
Variant 6US< 1 cmYesNoMRI abdomen without and with IV contrast
Variant 7CT (non-contrast or single-phase)< 1 cmYesNoMRI abdomen without and with IV contrast
MRI (non-contrast)CT abdomen with IV contrast multiphase
Variant 8US< 1 cmNoYesMRI abdomen without and with IV contrast
CT (non-contrast or single-phase)CT abdomen with IV contrast multiphase
MRI (non-contrast)
Table 3 Imaging features of common liver lesions

US
CT (non-contrast)
MRI
Enhancement pattern (CT and MRI)
Hepatic hemangiomaHyperechoicHypodense well-defined homogeneous lesionT1: HypointenseArterial phase: Discontinuous, peripheral, nodular
Well-defined homogeneousT2: Markedly hyperintenseEnhancement
lesions with acoustic enhancementPortal venous and delayed phases: Progressive
Rarely hypoechoic due to hepatic steatosisCentripetal filling
Hepatobiliary phase: Pseudo washout
Focal nodular hyperplasiaDifficult to detect (stealth lesion)Difficult to detect (stealth lesion)T1: Homogeneous isointense to slightly hypointense with hypointense stellate central scarArterial phase: Intense, homogenous enhancement
Portal venous and delayed phases: Isointense or slightly hyperintense to the liver parenchyma
Variable echogenicityHypodense or isodense well-defined lesions
T2: Isointense to slightly hyperintense
± Hyperintense central scar
Hepatobiliary phase: Isointense or slightly hyperintense to the liver parenchyma
± Central scar: Enhanced with extracellular gadolinium contrast agents, but not enhanced with HSCA
Hepatocellular adenomaHeterogenous, well-defined lesionsWell-defined heterogenous lesionT1: Variable signal intensity loss of signalArterial phase: Intense enhancement
Highly variable echogenicity± Hyperdense if hemorrhagic
± Hypodense if fattyOn opposed-phase if fatty
± Calcification in areas of old hemorrhageT2: Hyperintense
Hepatic cystAnechoic, well-defined, homogenous lesionWell-defined homogenous, hypodense lesionT1: HypointenseNo enhancement with contrast agents
T2: Hyperintense
Well-defined, homogenous lesion
Polycystic liver diseaseMultiple cysts with features, resembling hepatic cysts US findingsMultiple cysts with features, resembling hepatic cysts CT findingsMultiple cysts with features, resembling hepatic cysts MRI findingsNo enhancement with contrast agents
Mucinous cystic neoplasm of liverSolitary, well-defined, multiloculated anechoic lesion with septationsWell defined heterogenous lesionT1: Variable signal intensity± Enhancement of wall/septations
± CalcificationT2: Hyperintense
± Septal/mural nodules
± Calcification
CholangiocarcinomaHeterogenousHeterogenous hypodense lesion with capsular retraction and parenchymal atrophyT1: Heterogeneous hypointenseArterial phase: Peripheral, enhancement (targetoid appearance)
Variable echogenicity
± Hypoechoic rimT2: Peripherally hyperintense and centrally hypointensitePortal venous and delayed phases: Progressive, persistent heterogeneous enhancement
± Dilated intrahepatic bile ducts± Dilated intrahepatic bile ducts
± Satellite lesions± Satellite lesions
± Vascular encasement
Hepatocellular carcinomaVariable echogenicityEarly HCC, isodense, ± hypodense if fattyT1: Variable signal intensity, ± loss of signalArterial enhancement
Portal venous, delayed and hepatobiliary phases: Washout
Progressed HCC, isodense or hypodense, occasionally hyperdenseOn opposed-phase if fatty
T2: Variable signal intensity, typically moderately hyperintense
Table 4 Classification of hydatid cyst and imaging features
Gharbi
WHO-IWGE
US findings
CT findings
MRI findings
Type 1CE1Unilocular cyst with wallWell-defined hypoattenuating cystT1 hypointense
Hydatid sandPerceptible wall with mild delayed enhancementVery T2 hyperintense
Snowstorm signNo internal enhancementPerceptible wall with mild delayed enhancement
No internal vascularityNo internal enhancement
Type 3CE2Multilocular, multiseptated cystMultivesicular multiseptated cystMultivesicular multiseptated
Honeycomb signHypoattenuating daughter cystsT2 hyperintense daughter cysts
Daughter cystsNo septal enhancementNo septal enhancement
Type 2CE3Cyst with detached membrane, water-lily sign (CE3a)HeterogeneousHeterogeneous
Cyst with daughter vesicles in a solid matrix (CE3b)High-attenuating internal contentT2 hypointense detached membranes
Detached membranesNo internal enhancement
No internal enhancement
Type 4CE4Cyst with heterogenous contentSolid appearanceT2 iso- to hypointense
No daughter cystsNo daughter cystsNo daughter cysts
Ball of wool signAvascularAvascular
Type 5CE5Thick calcified wallCapsular and/or central calcificationsVery hypointense wall and intermediate to low internal signal intensity on T2-weighted images
Complete calcificationNo internal enhancement
No internal enhancement
Table 5 Stage-specific treatments of hepatic hydatid cysts recommended by World Health Organization Informal Working Group on Echinococcosis
WHO-IWGE classification
Surgery
Percutaneous treatment
Drug therapy
Suggested optimal treatment
CE1YesYes< 5 cm
Albendazole
> 5 cm
PAIR + Albendazole
CE2YesYesYesNon-PAIR percutaneous treatment + Albendazole
CE3aYesYes< 5 cm
Albendazole
> 5 cm
PAIR + Albendazole
CE3bYesYesYesNon-PAIR percutaneous treatment + Albendazole
CE4Watch and wait
CE5Watch and wait